
    
      This is a double-blind, parallel arm, placebo-controlled, multicentre, multinational, phase
      III study.

      To be eligible, patients must be in normal sinus rhythm at randomisation and must have an
      ECG-documented history of recent AF/AFL reverted to normal sinus rhythm by electrical,
      pharmacological or spontaneous conversion.
    
  